Stock & Company Details
Aclaris Therapeutics Inc $ACRS
Price:
46,691,331
140M
$739M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-1.28
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
ACRS technical indicators
Latest Aclaris Therapeutics Inc (ACRS) technical indicators as of 2026-06-30: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
68.80 8.5%
MACD:
0.16 27.0%
SMA 50:
$4.57 0.5%
SMA 200:
$3.34 0.5%
EMA 20:
$4.71 1.3%
Bollinger Bands:
5.22 / 3.98
Stochastic:
90.34 6.0%
ADX 14:
23.50 11.2%
ATR 14:
0.28 3.9%
CCI 20:
163.53 21.3%
OBV:
104.74M 3.1%
ROC 12:
21.05% 6.2%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Finance Bot
Ask your questions
Start by typing a question below.
